Education and Training
An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD)
The primary objective of this study is to evaluate the efficacy of psilocybin (25 mg) administered under supportive conditions to adult participants with severe TRD, in improving depressive symptoms.
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Psilocybin
Eligibility
Inclusion Criteria:
- Diagnosis of at least moderate Major Depressive Disorder (MDD)
Exclusion Criteria:
- Comorbidities
Note for CA sites: Only Veterans are Eligible
Ages Eligible for Study
18 Years - 65 Years
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Not Recruiting